Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 220

1.

The Glasgow Prognostic Score, an inflammation based prognostic score, predicts survival in patients with hepatocellular carcinoma.

Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Tanaka K, Fushiya N, Koike K, Nishino H, Matsushima M, Saeki C, Tajiri H.

BMC Cancer. 2013 Feb 2;13:52. doi: 10.1186/1471-2407-13-52.

2.

Inflammation scores predict survival for hepatitis B virus-related hepatocellular carcinoma patients after transarterial chemoembolization.

Zhou DS, Xu L, Luo YL, He FY, Huang JT, Zhang YJ, Chen MS.

World J Gastroenterol. 2015 May 14;21(18):5582-90. doi: 10.3748/wjg.v21.i18.5582.

3.

Comparison of the prognostic value of inflammation-based prognostic scores in patients with hepatocellular carcinoma.

Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Fushiya N, Koike K, Nishino H, Tajiri H.

Br J Cancer. 2012 Sep 4;107(6):988-93. doi: 10.1038/bjc.2012.354. Epub 2012 Aug 9.

4.

AFP level and histologic differentiation predict the survival of patients with liver transplantation for hepatocellular carcinoma.

Yaprak O, Akyildiz M, Dayangac M, Demirbas BT, Guler N, Dogusoy GB, Yuzer Y, Tokat Y.

Hepatobiliary Pancreat Dis Int. 2012 Jun;11(3):256-61.

5.

The C-reactive protein/albumin ratio, a novel inflammation-based prognostic score, predicts outcomes in patients with hepatocellular carcinoma.

Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Tanaka K, Fushiya N, Koike K, Nishino H, Matsushima M.

Ann Surg Oncol. 2015 Mar;22(3):803-10. doi: 10.1245/s10434-014-4048-0. Epub 2014 Sep 5.

PMID:
25190127
6.

The addition of C-reactive protein to validated staging systems improves their prognostic ability in patients with hepatocellular carcinoma.

Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Tanaka K, Fushiya N, Koike K, Nishino H, Matsushima M, Tajiri H.

Oncology. 2014;86(5-6):308-17. doi: 10.1159/000360704. Epub 2014 Jun 7.

PMID:
24924697
7.

Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.

Kim HS, Park JW, Jang JS, Kim HJ, Shin WG, Kim KH, Lee JH, Kim HY, Jang MK.

J Clin Gastroenterol. 2009 May-Jun;43(5):482-8. doi: 10.1097/MCG.0b013e318182015a.

PMID:
19197197
8.

Prognostic implication of serum vascular endothelial growth factor in advanced hepatocellular carcinoma staging.

Yegin EG, Siykhymbayev A, Eren F, Bekiroglu N, Ozdogan OC.

Ann Hepatol. 2013 Nov-Dec;12(6):915-25.

9.

The inflammation-based Glasgow Prognostic Score predicts survival in patients with cervical cancer.

Polterauer S, Grimm C, Seebacher V, Rahhal J, Tempfer C, Reinthaller A, Hefler L.

Int J Gynecol Cancer. 2010 Aug;20(6):1052-7. doi: 10.1111/IGC.0b013e3181e64bb1.

PMID:
20683416
10.

Modified Japan Integrated Staging is currently the best available staging system for hepatocellular carcinoma patients who have undergone hepatectomy.

Nanashima A, Sumida Y, Abo T, Shindou H, Fukuoka H, Takeshita H, Hidaka S, Tanaka K, Sawai T, Yasutake T, Nagayasu T, Omagari K, Mine M.

J Gastroenterol. 2006 Mar;41(3):250-6.

PMID:
16699859
11.

Elevated plasma fibrinogen levels are associated with a poor prognosis in patients with hepatocellular carcinoma.

Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Tanaka K, Fushiya N, Koike K, Nishino H, Matsushima M, Tajiri H.

Oncology. 2013;85(5):269-77. doi: 10.1159/000355502. Epub 2013 Nov 5.

PMID:
24217119
12.

A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System.

Hsu CY, Huang YH, Hsia CY, Su CW, Lin HC, Loong CC, Chiou YY, Chiang JH, Lee PC, Huo TI, Lee SD.

J Hepatol. 2010 Jul;53(1):108-17. doi: 10.1016/j.jhep.2010.01.038. Epub 2010 Mar 31.

PMID:
20451283
13.

Impact of an inflammation-based prognostic system on patients undergoing surgery for hepatocellular carcinoma: a retrospective study of 398 Japanese patients.

Ishizuka M, Kubota K, Kita J, Shimoda M, Kato M, Sawada T.

Am J Surg. 2012 Jan;203(1):101-6. doi: 10.1016/j.amjsurg.2010.09.030. Epub 2011 Mar 22.

PMID:
21429472
14.

Pretreatment serum C-reactive protein level predicts poor prognosis in patients with hepatocellular carcinoma.

Kinoshita A, Onoda H, Takano K, Imai N, Saeki C, Fushiya N, Miyakawa Y, Nishino H, Tajiri H.

Med Oncol. 2012 Dec;29(4):2800-8. doi: 10.1007/s12032-012-0220-1. Epub 2012 Mar 30.

PMID:
22460836
15.

An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma.

Pinato DJ, Sharma R.

Transl Res. 2012 Aug;160(2):146-52. doi: 10.1016/j.trsl.2012.01.011. Epub 2012 Jan 30.

PMID:
22677364
16.

Evaluation of the clinical features of HCC following hepatectomy for different stages of HCC.

Ma C, Chi M, Su H, Cheng X, Chen L, Kan Y, Wei W, Huang X, Li Y, Li L, Lin K, Huang Y, Wu Y, Huang X, Huang A, Liu J.

Hepatogastroenterology. 2012 Oct;59(119):2104-11. doi: 10.5754/hge12109.

PMID:
23435129
17.

Is liver resection justified in advanced hepatocellular carcinoma? Results of an observational study in 464 patients.

Ruzzenente A, Capra F, Pachera S, Iacono C, Piccirillo G, Lunardi M, Pistoso S, Valdegamberi A, D'Onofrio M, Guglielmi A.

J Gastrointest Surg. 2009 Jul;13(7):1313-20. doi: 10.1007/s11605-009-0903-x. Epub 2009 May 6.

PMID:
19418103
18.

The inflammation-based scores to predict prognosis of patients with hepatocellular carcinoma after hepatectomy.

Huang J, Xu L, Luo Y, He F, Zhang Y, Chen M.

Med Oncol. 2014 Apr;31(4):883. doi: 10.1007/s12032-014-0883-x. Epub 2014 Feb 18.

PMID:
24535607
19.

Hepatocellular carcinoma in uremic patients: is there evidence for an increased risk of mortality?

Lee YH, Hsu CY, Hsia CY, Huang YH, Su CW, Lin HC, Lee RC, Chiou YY, Huo TI.

J Gastroenterol Hepatol. 2013 Feb;28(2):348-56. doi: 10.1111/jgh.12062.

PMID:
23190248
20.

Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis.

Giannini EG, Marenco S, Borgonovo G, Savarino V, Farinati F, Del Poggio P, Rapaccini GL, Anna Di Nolfo M, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group.

Hepatology. 2012 Oct;56(4):1371-9. doi: 10.1002/hep.25814.

PMID:
22535689
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk